Tango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is anticipated to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Tango Therapeutics to post earnings of ($0.34) per share and revenue of $8.02 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Up 4.8 %

NASDAQ TNGX opened at $1.95 on Friday. The firm has a market cap of $210.81 million, a PE ratio of -1.65 and a beta of 0.87. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $4.70. Tango Therapeutics has a 52 week low of $1.72 and a 52 week high of $12.02.

Insider Transactions at Tango Therapeutics

In other news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 24,268 shares of company stock valued at $72,561. Corporate insiders own 6.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $12.33.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.